Objective: Microglia play a pivotal role in the initiation and progression of Alzheimer's disease (AD). We here tested the therapeutic hypothesis that the Ca 2+ -activated potassium channel KCa3.1 constitutes a potential target for treating AD by reducing neuroinflammation. Methods: To determine if KCa3.1 is relevant to AD, we tested if treating cultured microglia or hippocampal slices with Ab oligomer (AbO) activated KCa3.1 in microglia, and if microglial KCa3.1 was upregulated in 5xFAD mice and in human AD brains. The expression/activity of KCa3.1 was examined by qPCR, Western blotting, immunohistochemistry, and whole-cell patch-clamp. To investigate the role of KCa3.1 in AD pathology, we resynthesized senicapoc, a clinically tested KCa3.1 blocker, and determined its pharmacokinetic properties and its effect on microglial activation, Ab deposition and hippocampal long-term potentiation (hLTP) in 5xFAD mice. Results: We found markedly enhanced microglial KCa3.1 expression/activity in brains of both 5xFAD mice and AD patients. In hippocampal slices, microglial KCa3.1 expression/activity was increased by AbO treatment, and its inhibition diminished the proinflammatory and hLTP-impairing activities of AbO. Senicapoc exhibited excellent brain penetrance and oral availability, and in 5xFAD mice, reduced neuroinflammation, decreased cerebral amyloid load, and enhanced hippocampal neuronal plasticity. Interpretation: Our results prompt us to propose repurposing senicapoc for AD clinical trials, as senicapoc has excellent pharmacological properties and was safe and well-tolerated in a prior phase-3 clinical trial for sickle cell anemia. Such repurposing has the potential to expedite the urgently needed new drug discovery for AD.
Introduction
Emerging evidence strongly implicates aberrant microglial activation in Alzheimer's disease (AD). [1] [2] [3] The functional and pathological diversity of microglia is orchestrated by a complex ensemble of ion channels, receptors, and transporters that regulate intracellular signaling and gene expression. Activities of these surface molecules can be modulated selectively in order to modify microglial activation. One possible target is KCa3.1, an intermediateconductance Ca 2+ -activated K + channel expressed in immune cells such as T-lymphocytes, macrophages and microglia. 4, 5 In these cells, KCa3.1 regulates cellular activation, migration and proliferation via K + efflux, which helps maintain a negative membrane potential to drive Ca 2+ influx required for various activities. 6, 7 We and others previously demonstrated that rat 8 and mouse 9 microglia express KCa3.1, but do not display other KCa currents carried by KCa1.1 and KCa2 channels. 9 We further demonstrated that microglial activation and neurotoxicity induced by Ab oligomer (AbO), the most toxic amyloid in AD brains, can be blocked by the specific KCa3.1 blocker TRAM-34 in vitro, suggesting that KCa3.1 could be a therapeutic target for AD. 9, 10 In the current study, we used animal models and human postmortem brain samples to show that KCa3.1 is a biologically relevant and microglial target for AD. We further showed that an orally available KCa3.1 inhibitor called senicapoc was able to mitigate AD-like deficits in 5xFAD mice. We further found that senicapoc exhibited good brain penetration (C brain /C plasma~5 ). Senicapoc was previously advanced to a Phase-3 clinical trial for sickle cell anemia and was found to be safe and well-tolerated. [11] [12] [13] Our results provide a strong rationale to repurpose senicapoc for the treatment of AD and/or mild cognitive impairment.
Methods and Materials Study approval
All protocols involving mouse models were approved by the Institutional Animal Care and Use Committee. Human brain samples were provided by the University of California Davis Alzheimer's Disease Center, approved by the Institutional Review Board.
Mouse model
Tg6799 5xFAD mice on the C57Bl/6 background were obtained from Dr. Robert Vassar.
14 This line co-expresses human APP695 with the Swedish (K670N, M671L), Florida (I716V), and London (V717I) mutations and human PS1 harboring M146L and L286V mutations. Mice were randomly assigned to treatment groups and phenotyping parameters were evaluated in a blinded manner. Roughly equal numbers of male and females mice were used.
Chemicals and diets
TRAM-34 and 4-phenyl-4H-pyran (methyl-5-acetyl-4-(4-chloro-3-(trifluoromethyl)phenyl)-2,6-dimethyl-4H-pyran-3-carboxylate) were synthesized as described. 15 Senicapoc was synthesized as shown in Figure 6A and its purity and identity authenticated (Data S1). For intraperitoneal administration of TRAM-34, animals received either the vehicle Miglyol-812 (caprylic/capric triglyceride, Spectrum Chemicals) or TRAM-34 (40 mg/kg) dissolved in Miglyol-812. For diet administration of senicapoc, animal received either a senicapoc-medicated diet (2400 ppm, Harlan TD.140594) or a control diet (Harlan TD.140368).
Tissue culture and acute isolation of microglia
Primary microglia were prepared from mixed glia cultures as described. 9 Hippocampal slice cultures (400 lm thick) were prepared from 7-day-old C57BL/6 mice as described 9 and cultured for 10 days before use. To study microglia in adult mouse brains without culturing, microglia were acutely isolated as described using antiCD11b magnetic beads (Miltenyi Biotec). 16 
Production of AbO
AbO was prepared and characterized as described. 16 To ensure consistency, a random sample from each batch was evaluated for neurotoxic activity and ability to rapidly induce exocytosis of MTT formazan, as described. 17, 18 Whole-cell patch-clamp Whole-cell patch-clamp studies on cultured primary microglia and isolated adult microglia were conducted as described. 9, 16, 19 KCa3.1 conductances were calculated from the slope of the TRAM-34-sensitive K Ca current between À80 and À75 mV, where, under our recording conditions with an aspartate-based internal solution, KCa3.1 currents are primarily carried by KCa3.1 and not "contaminated" with Kv1.3 (which activates at voltages more positive than À40 mV), inward rectifier K + currents (which are appreciable at voltages more negative than À80 mV), or chloride currents.
Cell/tissue homogenate preparation, Western blot analysis, and Ab ELISA To obtain cell lysates, cells were washed with ice-cold PBS and incubated and harvested with a lysis buffer (150 mmol/L NaCl, 10 mmol/L NaH 2 PO 4 , 1 mmol/L EDTA, 1% TritonX100, 0.5% SDS) with protease inhibitor cocktail and phosphatase inhibitor (Sigma). Mouse and human brain were homogenized in RIPA buffer (ThermoFisher) with protease inhibitor cocktail and phosphatase inhibitor (Sigma) and used for Western blotting as described. 9 The following primary antibodies (dilutions) were used: anti-KCa3.1 P4997 (1:1000, Sigma), anti-phospho P38MAPK and anti-P38MAPK (1:1000, Cell Signaling), anti-b actin (1:3000, Sigma), and anti-GAPDH (1:2000, Cell Signaling). Secondary antibodies were HRPconjugated anti-rabbit or anti-mouse antibody (1:1000, GE Healthcare). Brain tissue samples from 5xFAD treated with senicapoc or control diet were fractionated into TBS-soluble and TBS-insoluble, SDS-soluble fractions, which were used for Ab42 quantification by a Human Ab42 ELISA kit (Wako) as described. 16 Alternatively, Ab in each fraction was separated in 16.5% Tris/Tricine SDS gel electrophoresis (Bio-Rad), transferred to PVDF membrane, and detected by anti-Ab (6E10, 1:1000, BioLegend).
Plus Mini Kit (Qiagen) or RNeasy Plus Universal Mini Kit (Qiagen). RNA samples from acutely isolated microglia were further reverse-transcribed and pre-amplified as we previously described. 20 The result was normalized to b-actin. The primer sequences used are listed in Table 1 . Relative cDNA levels for the target genes were analyzed by the 2-ΔΔCt method using Actb as the internal control for normalization.
Immunofluorescence staining
Immunofluorescence staining and quantification was performed as described. 16 Briefly, microglia cells cultured on cover slip, hippocampal slices and frozen mouse or human brain sections (20 lm 16 For co-localization analysis to determine % of microglia expressing KCa3.1, three photomicrographs from each mouse were analyzed by a Fiji Coloc2 plugin (co-localization analysis program, https:// imagej.net/Coloc_2). The photography and analysis of immunoreactivity were conducted in an investigatorblinded manner.
Induction of hippocampal long-term potentiation by high frequency stimulation
See Data S1.
Pharmacokinetic study of senicapoc
Total senicapoc plasma and brain concentrations were determined by LC-MS analysis using a Waters Acquity UPLC (Waters) interfaced to a TSQ Quantum Access Max mass spectrometer (ThermoFisher Scientific) (Data S1). Basic pharmacokinetic properties (brain/plasma ratios; brain/plasma profiles and oral availability) are shown in Figure 6 .
Statistics
All results were expressed as the mean AE S.E, or mean AE S.D. in pharmacokinetics data. Normality of the data distribution was determined using the Shapiro-Wilk test. For group comparisons in means, paired or unpaired Student's t-test or one or two-way ANOVA, as appropriate, were conducted using the SigmaStat 3.1 (Systat Inc.). When the overall ANOVA was significant, Bonferroni's Table 1 . qPCR primer list.
Gene
Forward Primer (5 multiple comparison procedure was carried out to maintain the family wise error rate at 0.05. The significance level for the two-sided analyses was set at P < 0.05. If the assumption of normality was violated, a natural log transform of the outcome was used and reassessed for normality. If normality was still violated, a nonparametric Wilcoxon rank sum test was used instead of the t-test.
Results

KCa3.1 is upregulation by AbO in microglia
Previously we and others have verified the biophysical and pharmacological signatures of KCa3.1 in primary cultured or acutely isolated adult mouse, rat, and human microglia, and shown that KCa3.1 plays an important role in regulating microglial activation. 9, 23, 24 Expression analysis further showed that only microglia expressed significant amounts of KCa3.1 among neural cells (Fig. 1A) . In organotypic hippocampal slice cultures, a more physiological model, AbO substantially increased the number of strongly CD11b-immunoreactive microglia, a large majority of which were also KCa3.1-positive (Fig. 1B) . qPCR ( Fig. 1C ) and Western blotting ( Fig. 1D ) further showed parallel increases in the transcript and protein levels of KCa3.1. We did not observe significant co-localization of the astrocytic marker GFAP with KCa3.1, suggesting that AbO did not upregulate KCa3.1 in astrocytes (Fig. 1B) .
Microglial KCa3.1 expression/activity is enhanced in 5xFAD mouse and human AD brains
To investigate the in vivo role of microglial KCa3.1, we used 5xFAD mice, which harbor five familial mutations of APP and PSEN1 genes and show robust Ab production and Ab-associated neuroinflammation.
14 Soluble AbO made of Ab42 is a major species of Ab aggregates in 5xFAD mice 25 and could stimulate microglial KCa3.1 expression in vivo. We observed substantial increases in both CD11b and KCa3.1 immunoreactivities in four and ten monthsold 5xFAD brains ( Fig. 2A , D, and Fig. S1 ) compared to age-matched Wt littermates. Two antibodies, APC064 and P4997, were used and both showed that KCa3.1 was localized to CD11b-positive microglial cell bodies or processes ( Fig. 2A ). Higher magnification revealed that KCa3.1 appeared distributed differently from CD11b within microglia. For example, KCa3.1 immunostaining was localized to segments of microglial processes, contiguous (Fig. 2B , arrowheads) or overlapping with CD11b-positive curvilinear profiles. qPCR ( Fig. 2C ) and Western blotting (Fig. 2D ) confirmed the increased level of KCa3.1 transcript and protein, respectively, in 5xFAD brains. Notably, KCa3.1 expression was not different between Wt and 5xFAD mice at one month of age, but began to increase in 5xFAD mice at 4 months of age. This appears to concomitant with Ab amyloidosis and microglial activation in 5xFAD mice, which began at 3-4 months of age.
To confirm that KCa3.1 in 5xFAD microglia is functional, we performed whole-cell patch-clamp on microglia acutely isolated from brains of 10-months-old 5xFAD and Wt littermates. The purity of isolated microglia, determined by flow cytometry, was consistently between 94 to 96%. 26 Compared to Wt microglia (Fig. 3A) , 5xFAD microglia displayed enhanced expression of a TRAM-34-sensitive KCa3.1 current when dialyzed with 1 lmol/L of free Ca 2+ (Fig. 3B) . The K + current remaining after application of 1 lmol/L of TRAM-34 was carried by a combination the voltage-gated Kv1.3 current (at potentials above À40 mV) and the inward-rectifier Kir2.1 (at potentials below À90 mV), two other major K + currents expressed in microglia. 16, 27 Quantification of the TRAM-34-sensitive current density, which puts the current amplitude in relation to cell size, shows a significant increase in functional KCa3.1 expression in 5xFAD microglia (Fig. 3C) .
We next compared KCa3.1 expression in the superior temporal cortex of thirteen pathologically confirmed AD ("high likelihood of AD" according to the National Institute on Aging-Alzheimer's Association guideline 28 and Braak stage 5 and 6 according to the BrainNet Europe criteria 29 ) and nine age-matched control (cognitively intact with Braak stage 0-2) individuals (Table 2) . Immunofluorescence stains highlighted strongly KCa3.1-positive microglia in AD brains that were much less numerous in control brains (Fig. 4A ). KCa3.1 immunoreactivities, assessed by two independent antibodies, were accentuated in or around FSB-positive amyloid plaques and showed substantial co-localization with Iba-1, a microglia marker (Fig. 4B, arrows) . Interestingly, KCa3.1 appeared distributed differently from Iba-1 within same microglia. Substantial co-localization was also found with CD68, a microglia/macrophage marker, but not with GFAP, an astrocytic marker (Fig. S2) . Western blotting showed that human brains express a KCa3.1-immunoreactive band slightly below the 50 kDa mark, consistent with that seen in mouse brains and a predicted molecular mass of 47.7 kDa (Fig. 4C) . Quantitation of KCa3.1 band intensities revealed a substantial increase in AD brains compared to control brains (Fig. 4D ). receptor-dependent hLTP. Notably, minocycline (a tetracycline inhibitor of microglial activation) and iNOS reduction were found to prevent the hLTP disruption by Ab, 30 suggesting that microglial activation and microglial NO production contribute to the detrimental effect of Ab on synaptic function. Because KCa3.1 inhibition blocks AbO-induced microglial neurotoxicity as well as NO production in hippocampal slices, 9 we hypothesized that KCa3.1 blockade is able to prevent the microglia-related deleterious effect of AbO on hLTP. Indeed, in the hLTP induced in Schaffer-collateral-CA1 synapses following high frequency stimulation, application of AbO to mouse hippocampal slices blocked hLTP induction at 20-100 nmol/L. 16 Co-perfusion of TRAM-34 recovered hLTP from AbO-induced reduction (Fig. 5A and B) .
To determine if such an effect can be demonstrated in vivo, we used 5xFAD mice, for whom AbO-related hLTP deficits have been demonstrated. 31 We intraperitoneally injected TRAM-34 (40 mg/kg) or vehicle into 12-month-old 5xFAD mice and age-matched Wt littermates, sacrificed them at 24-hours post-injection, and obtained hippocampal slices for recording. The magnitude of hLTP induction was significantly reduced in 5xFAD mice compared to Wt littermates, but was significantly increased to the Wt level in TRAM-34-treated 5xFAD mice ( Fig. 5C and D) . Taken together, our data suggest that KCa3.1 blockade ameliorates neuroinflammation and associated synaptic impairments induced by AbO.
Senicapoc is an orally available, brain penetrant KCa3.1 blocker Although TRAM-34 readily passes the blood brain barrier (C brain /C plasma = 1.2) 32 and is widely used as a tool compound for proof-of-concept rodent studies, it is not optimal for clinical use due to its lack of oral availability and short half-life. 33 To identify a clinically promising KCa3.1 inhibitor, we investigated the pharmacokinetic properties and the brain penetration of two other published KCa3.1 blockers: a phenyl-pyran, reported by chemists at Bayer, 34 and senicapoc 35 (Fig. 6A) . The Bayer 4-phenyl-4H-pyra exhibited good brain penetration (C brain /C plasma~3 ) but had a short half-life of 15 min following intravenous administration at 10 mg/kg in mice (data not shown). We next resynthesized senicapoc (Fig. 6A) , an orally available KCa3.1 blocker structurally similar to TRAM-34. 12 The purity of our senicapoc preparations was 96.9% (see Data S1). Despite its long (~7 day) half-life in humans, 12 senicapoc exhibited a relatively short but pharmacologically acceptable half-life of roughly 1 h in mice and 4 h in rats (data not shown). Its brain concentrations on average were 5-7 times higher than plasma concentrations in both mice and rats (Fig. 6B) . At one hour after intraperitoneal injection at 50 mg/kg, brain concentrations averaged 43 AE 8 lmol/L (n = 3) in mice and 43 AE 7 lmol/L (n = 2) in rats. A more detailed time course in mice revealed that senicapoc brain concentrations were significantly higher than plasma concentrations for at least 6 h after intraperitoneal administration (Fig. 6C) . Senicapoc further achieved good plasma concentrations following oral gavage administration ( Fig. 6D ) with an oral availability of roughly 60%. 
Senicapoc rectifies Ab-related microglial activation and neurotoxicity
Despite senicapoc's structural similarity to TRAM-34 and its demonstrated selectivity for KCa3.1, 35, 36 its effect on microglial activation has not been studied. We next determined if senicapoc rectifies AbO-induced microglial abnormalities. In primary microglial cultures, senicapoc was able to block AbO-induced microglial KCa3.1 currents (Fig. 7A), microglial proliferation (Fig. 7B) , expression of microglial activation mediators IL-1b, IL-6 and iNOS (Fig. 7C) , activation of p38MAPK (Fig. 7D) , and production of NO (Fig. 7E) . These in vitro effects are identical to those reported for TRAM-34. 9 We subsequently tested the in vivo effects of senicapoc by feeding six-month-old 5xFAD mice with a senicapoc-medicated diet. To determine if this medicated diet was able to achieve pharmacologically relevant senicapoc concentrations, we measured the morning (9 am) plasma and brain levels in two weeks after starting the diet. The result showed that brain senicapoc levels ranged between 1 and 2.5 lmol/L (Fig. S3) . Considering senicapoc's IC 50 of 11 nmol/L for KCa3.1 inhibition and its protein binding of 95%, such brain concentrations are sufficient to exert a pharmacodynamic effect. 35, 36 Following ad lib access to the medicated diet for three months, senicapoc curbed microglial activation as evidenced by reduced CD11b immunoreactivity (45% reduction, P < 0.001, Fig. 8A ). Similar reductions in Iba-1 and CD68 immunoreactivities were also observed (Fig. S4) . Senicapoc treatment also significantly reduced the number of microglia expressing KCa3.1 (Fig. 8B) . qPCR showed significantly reduced expressions of proinflammatory modulators IL-1b, TNF-a, IL-6, and iNOS (Fig. 8C ), but no changes in several markers typical of an M2-like phenotype (Fig. S5) . Interestingly, it also resulted in a 39% reduction (P < 0.001) of cerebral amyloid deposits (Fig. 8A) . Levels of TBS-soluble and TBS-insoluble/SDS-soluble Ab142 were reduced 22% and 35%, respectively, when measured by ELISA (Fig.  8D ). This observation was corroborated with Western blotting for Ab following Tricine gel electrophoresis (Fig. 8E) .
As reductions of soluble Ab species and microglial activation following senicapoc treatment may help mitigate synaptic impairment, we further tested if KCa3.1 inhibition by senicapoc in vivo would improve hLTP. 31 Indeed, we found that senicapoc treatment rectified the reduced induction of hLTP in 5xFAD mice to the level of Wt mice ( Fig. 8F and G) . 
Discussion
Therapies aimed at microglia face several challenges as activated microglia can exert both beneficial and harmful effects in AD. Such therapies should ideally: (1) achieve reduced neurotoxicity while maintaining or enhancing neuroprotective functions of microglia, such as phagocytosis of Ab aggregates; (2) be relatively specific to microglia to avoid adversely affecting important neuronal functions; (3) not be broadly immunosuppressive. We consider inhibition of KCa3.1 would selectively modulate microglial activation by "fine-tuning" Ca 2+ signaling and selectively modulating activation signaling pathways. Evidence from our laboratory and others' indicates that KCa3.1 blockers inhibit microglia-mediated neurotoxicity without affecting microglial migration and phagocytosis. [4] [5] [6] [7] [8] [9] [10] Moreover, KCa3.1 blockers are very mild immunosuppressants that do not affect the ability of rodents to clear infections. 10 Therefore in this study, we intended to use animal models and human postmortem brain samples to show that KCa3.1 is a biologically relevant and microglial target for AD. Several conclusions can be drawn: (1) soluble AbO, the highly toxic Ab species implicated as one of the principal initiators of AD phenotypes, enhances microglial KCa3.1 activity; (2) KCa3.1 is required for AbO-induced microglial proinflammatory activation and neurotoxicity; (3) KCa3.1 expression/activity is upregulated in transgenic AD animals and human AD brains; and (4) pharmacological inhibition of KCa3.1 with TRAM-34 or senicapoc in mice mitigates some key ADlike phenotypes including neuroinflammation, hLTP deficit and amyloid pathology. Our study supports that KCa3.1 is a candidate therapeutic target for AD.
KCa3.1 appears particularly upregulated in amyloid plaque-associated microglia, notably in human AD brains (Fig. 4) . Recent evidence suggests that plaque-associated microglia and plaque-distant microglia are in different activation states, 37 with plaque-associated microglia exhibiting a "hyperactive" state. 38 Plescher et al. found that, in acute cerebral slices of the TgCRND8 mouse model of AD, plaque-associated microglia expressed significant Kv and Kir currents with the latter most likely attributed to Kir2.1.. 37 This result is consistent with our previous finding of enhanced microglial Kv and Kir2.1 activity/expression in 5xFAD mice, 16 but the role of KCa3.1 was not investigated. It would be interesting in future experiments using single-cell approaches to determine the KCa3.1 expression and activity in plaque-associated microglia or in "disease-associated microglia (DAM)", a unique microglia-type recently identified in 5xFAD mice that has the potential to restrict neurodegeneration, 39 and to test if inhibition of KCa3.1 in such subgroups of microglia affects their disease-related phenotype.
The significance of microglia in modulating AD-like amyloid pathology remains controversial. Our in vivo data ( Fig. 8A-E ) of substantial reductions of soluble and insoluble Ab species in mice chronically treated with senicapoc suggest that KCa3.1 inhibition may enhance the microglial Ab clearance capacity that is suppressed in AD transgenic mice. 40, 41 Our result is consistent with several reports showing that modulation of specific microglial signaling pathways alters Ab deposition and clearance, 40, [42] [43] [44] [45] [46] [47] but appears contradictory to reports showing that inducible microglia depletion by genetic or pharmacological means fails to affect amyloid pathology in transgenic AD models. 48, 49 Although further studies are needed to resolve this controversy, our data using K + channel expression as a readout show that the microglial activation profiles in transgenic AD mice are complex. 16 Therefore, differences in the timing and approaches of neuro-immunomodulation to alter microglia quantity or signaling may differentially influence the outcomes.
One limitation of our study is that we could not demonstrate significant memory deficits in 5xFAD/control diet mice compared to Wt mice at 9 months of age despite their large cerebral amyloid load, therefore the Figure 8 . The effect of chronic oral senicapoc treatment in 5xFAD mice. Six-month-old 5xFAD and Wt littermates were fed ad lib senicapocmedicated or control diet (n = 9 per group) for three months and the brains removed for analysis. (A) Frontal cortex sections co-stained with antiCD11b and FSB showed that senicapoc diet reduced the CD11b and FSB reactivities in 5xFAD brains. (B) Frontal cortex sections co-stained with anti-CD11b and anti-KCa3.1 (APC064) were analyzed by co-localization analysis. 5xFAD mice showed increased % of microglia expressing KCa3.1, which was reduced by senicapoc treatment. (C) The transcript levels of indicated proinflammatory modulators in acutely isolated microglia were increased in 5xFAD mice consuming control diet, compared to the Wt littermates. Senicapoc diet reduced the expression of all four modulators. Two-way ANOVA follow by Bonferroni post hoc test. (D) The fresh brains were fractionated into TBS-soluble and TBS-insoluble, SDS-soluble fractions, which were used for ELISA quantification of Ab42. Senicapoc diet significantly reduced the levels of Ab42 in both fractions. Two-way ANOVA follow by Bonferroni post hoc test. (E) The ELISA result was corroborated with Tricine gel electrophoresis/Western blotting, which showed reduced Ab band (arrow) intensities in both TBS-solule and SDS-soluble fractions of 5xFAD brains. (F) Traces and time course of hLTP induced with HFS. (G) Summary bar graphs showing the average fEPSP slope between 50 and 60 min, compiled from recordings of Wt/control (eight slices from five mice), Wt/Senicapoc (eight slices from five mice), 5xFAD/control (12 slices from six mice), and 5xFAD/senicapoc (10 slices from six mice). Data are expressed as mean percent change in fEPSP slope AE SE. from baseline. Two-way ANOVA follow by Bonferroni post hoc test. *P < 0.005, **P < 0.001. 5xFAD mice on control diet had reduced amplitudes of hLTP but this reduction was mitigated by senicapoc diet.
cognitive benefit of senicapoc could not be demonstrated in our current trial. Two tasks were tested: novel object recognition and step-through passive avoidance. Using these two tests, we did successfully demonstrated deficits in 10-month-old APP/PS1 [B6.Cg-Tg(APPswe,PSEN1dE9) 85Dbo/Mmjax] mice in our prior study, 16 arguing against technical issues. Future therapeutic trials using alternative models and larger numbers of animals are warranted.
Based on our data, here we propose repurposing senicapoc for AD treatment. Drug repurposing offers a rapid and economic route to the clinic than new drug discovery, which on average takes at least 15 years and $1.5 billion to bring a new successful drug to the market. It is therefore advantageous to reposition known targets, such as KCa3.1, for which a wealth of pharmacological knowledge has been accumulated, and safety has been demonstrated. Our finding that senicapoc is brain penetrant (C brain /C plasma~5 ) and orally available makes it suitable for the potential treatment of AD. Senicapoc was initially developed for sickle cell anemia. Since K + efflux through KCa3.1 is a major pathway for erythrocyte dehydration during sickling, 50 it appeared very promising to test KCa3.1 inhibitors, which had been shown to prevent erythrocyte dehydration in both patients 51 and mouse models. 52 The Phase-2 clinical trial showed that senicapoc reduced hemolysis and increased hemoglobin levels. 12 However, in Phase-3, senicapoc failed to achieve its primary clinical end-point, which was reduction in the rate of vaso-occlusive pain crisis, despite clearly improving all hematological parameters. 53 Since senicapoc were demonstrated safe and well-tolerated in humans, it was deposited in the NIH National Center for Advancing Translational Research (NCAT) library as PF-05416266, making it available for investigatorinitiated clinical trials. In conclusion, our preclinical data support that repurposing of senicapoc has the potential to expedite the urgently needed new drug discovery for AD.
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